Language:

Remdesivir for the Treatment of Covid-19 — Preliminary Report

The New England journal of medicine, 2020-09, Vol.383 (10), p.992-994 [Peer Reviewed Journal]

Full text available

Citations Cited by

Title:
Remdesivir for the Treatment of Covid-19 — Preliminary Report
Author: Gillenwater, Samantha ; Rahaghi, Franck ; Hadeh, Anas ; McMahon, James H ; Udy, Andrew ; Peleg, Anton Y ; McCaw, Zachary R ; Kim, Dae H ; Wei, Lee-Jen ; Olalla, Julián ; Beigel, John H ; Tomashek, Kay M ; Dodd, Lori E
Subjects: Coronaviruses ; COVID-19 ; Respiratory diseases ; Sepsis
Is Part Of: The New England journal of medicine, 2020-09, Vol.383 (10), p.992-994
Description: To the Editor: We would like to direct attention to the enrollment criteria in the trial described in the article by Beigel et al. (published online on May 22 at NEJM.org). 1 In patients with Covid-19–related respiratory disease, these criteria resulted in the use of remdesivir well into the illness. The median time from symptom onset to randomization was 9 days. In an analysis involving patients with community-acquired pneumonia, Daniel et al. found an increased mortality at 30 days when the time to administration of the first antibiotic was 4 hours or longer. 2 Clinicians have followed the recommendations of the Surviving . . .
Publisher: Boston: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMc2022236
Source: ProQuest One Psychology
AUTh Library subscriptions: ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Searching Remote Databases, Please Wait